OA09478A - "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation". - Google Patents

"Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".

Info

Publication number
OA09478A
OA09478A OA59940A OA59940A OA09478A OA 09478 A OA09478 A OA 09478A OA 59940 A OA59940 A OA 59940A OA 59940 A OA59940 A OA 59940A OA 09478 A OA09478 A OA 09478A
Authority
OA
OAPI
Prior art keywords
myristoyl
treatment
phenylalaine
myristoylation
production
Prior art date
Application number
OA59940A
Other languages
English (en)
French (fr)
Inventor
Vincent Michel
Remond Georges
Herve Yolande
Boutin Jean-Albert
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of OA09478A publication Critical patent/OA09478A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA59940A 1990-01-25 1991-01-25 "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation". OA09478A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
OA09478A true OA09478A (fr) 1992-11-15

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59940A OA09478A (fr) 1990-01-25 1991-01-25 "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".

Country Status (14)

Country Link
US (1) US5164414A (da)
EP (1) EP0443891B1 (da)
JP (1) JPH0717503B2 (da)
AT (1) ATE94387T1 (da)
AU (1) AU633395B2 (da)
CA (1) CA2034861A1 (da)
DE (1) DE69100364T2 (da)
DK (1) DK0443891T3 (da)
ES (1) ES2060310T3 (da)
FR (1) FR2657259A1 (da)
IE (1) IE65573B1 (da)
OA (1) OA09478A (da)
PT (1) PT96571A (da)
ZA (1) ZA91574B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
WO2003007876A2 (en) * 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2013013302A1 (en) * 2011-07-22 2013-01-31 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
JP6209588B2 (ja) 2012-03-30 2017-10-04 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシルプロリン誘導体
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
CN104244734B (zh) 2012-03-30 2018-04-03 奇华顿股份有限公司 作为食品加香化合物的n‑酰化1‑氨基环烷基羧酸
JP6250029B2 (ja) 2012-03-30 2017-12-20 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル−アミノ酸誘導体
CN104219965B (zh) 2012-03-30 2018-10-12 奇华顿股份有限公司 作为食品加香化合物的γ氨基-丁酸和β丙氨酸的N-酰基衍生物
CN104254253B (zh) 2012-03-30 2017-12-29 奇华顿股份有限公司 作为食品加香化合物的n‑酰化甲硫氨酸衍生物
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10674755B2 (en) 2013-10-02 2020-06-09 Givaudan S.A. Organic Compounds
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
CN105636934B (zh) 2013-10-02 2019-03-29 奇华顿股份有限公司 N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物
CN105636457B (zh) 2013-10-02 2020-03-10 奇华顿股份有限公司 具有味道改进特性的有机化合物
US10834950B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds
WO2015050537A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
ES2964607T3 (es) 2015-07-17 2024-04-08 Pacylex Pharmaceuticals Inc Silenciamiento epigenético de NMT2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II

Also Published As

Publication number Publication date
DE69100364D1 (de) 1993-10-21
FR2657259B1 (da) 1994-08-19
ZA91574B (en) 1991-11-27
IE65573B1 (en) 1995-11-01
US5164414A (en) 1992-11-17
DK0443891T3 (da) 1993-12-27
DE69100364T2 (de) 1994-04-21
IE910242A1 (en) 1991-07-31
AU6998791A (en) 1991-08-01
JPH0717503B2 (ja) 1995-03-01
ATE94387T1 (de) 1993-10-15
JPH04210916A (ja) 1992-08-03
ES2060310T3 (es) 1994-11-16
FR2657259A1 (fr) 1991-07-26
PT96571A (pt) 1991-10-15
EP0443891A1 (fr) 1991-08-28
AU633395B2 (en) 1993-01-28
CA2034861A1 (fr) 1991-07-26
EP0443891B1 (fr) 1993-09-15

Similar Documents

Publication Publication Date Title
OA09478A (fr) "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".
AU1808488A (en) Compounds for the treatment of alzheimer's disease
OA07291A (fr) Gilet orthopédique de soutien et de contention dans le traitement des traumatisés et des opérés de l'épaule, de la ceinture scapulaire et du membre supérieur.
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
FR2662354B1 (fr) Utilisation du baclofene pour l'obtention de medicaments destines au traitement de l'angine de poitrine.
IT8224839A0 (it) Polimeri reattivi per la cura di affezioni cutanee.
FR2617061B1 (fr) Pulverisateur portable de liquide, notamment pour le traitement de la vegetation
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
OA09123A (fr) Composition pharmaceutique pour la prévention des maladies sexuellement transmissibles.
BG94738A (bg) Използване на разтвор на йод за лечение на заболявания, свързани с йодна недостатъчност
NZ504419A (en) The use of carvedilol for treating amyloid diseases such as Alzheimer's
MD306B1 (ro) Remediu pentru profilaxia afectiunilor vasculare determinate de actiunea peroxizilor glicoproteinfixati
FR2510889B1 (fr) Medicament contenant certains phosphates ribofurannosyl-3',5'-cycliques substitues en 6, 8 pour le traitement de maladies proliferatives de la peau
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
GR3006674T3 (da)
FI852730A0 (fi) (pyrrol-1-yl) -fenyl-dihydropyridazinoner, deras framstaellning och anvaendning.
MC2246A1 (fr) Utilisation de trinitrobenzenes ou d'acide carminique dans le traitement du cancer ou des maladies virales
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques